RecruitingNot Applicable

Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China

China4,000 participantsStarted 2025-11-03

Plain-language summary

This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achievement (\<1.8 mmol/L) in acute ischemic stroke or TIA patients under Evolocumab treatment within 12 months post-intervention.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age≥18 years as of the screening date;
✓. Patients with non-cardioembolic ischemic stroke or TIA within 3 months prior to the screening date;
✓. Prescribed Evolocumab at physician's discretion;
✓. Signed informed consent.

Exclusion criteria

✕. Intracranial hemorrhagic diseases: such as cerebral hemorrhage, subarachnoid hemorrhage, etc.;
✕. Patients confirmed by baseline head CT or MRI to have hemorrhage or other pathological brain diseases, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis);
✕. Silent cerebral infarction without signs and symptoms;
✕. Participation in a clinical trial of another drug or device in the past 3 months or ongoing at the time of the screening date;
✕. Any prior use of Evolocumab or other PCSK9 inhibitor treatments within the past 6 months prior to the screening date;
✕. Life expectancy \<12 months or unable to complete the research for other reasons as of the screening date;
✕. Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders;
✕. Refusal to participate in the enrollment survey.

What they're measuring

Proportion of acute ischemic stroke or TIA patients achieving LDL-C <1.8 mmol/L at 1 year with Evolocumab treatment

Timeframe: at 365 days (±14days）

Trial details

NCT IDNCT07143149

SponsorBeijing Tiantan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-03-31

Contact for this trial

Jie Xu

59975672 xujie@ncrcnd.org.cn

View on ClinicalTrials.gov More Ischemic Stroke trials